Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Lisa M, Arellano, Martha, Holloway, Stacie, Shepard, Marian, McMillan, Stephanie, Khoury, Hanna Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262317/
https://www.ncbi.nlm.nih.gov/pubmed/22282699
http://dx.doi.org/10.2147/JBM.S7158
_version_ 1782221702972833792
author Lima, Lisa M
Arellano, Martha
Holloway, Stacie
Shepard, Marian
McMillan, Stephanie
Khoury, Hanna Jean
author_facet Lima, Lisa M
Arellano, Martha
Holloway, Stacie
Shepard, Marian
McMillan, Stephanie
Khoury, Hanna Jean
author_sort Lima, Lisa M
collection PubMed
description Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.
format Online
Article
Text
id pubmed-3262317
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32623172012-01-26 Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia Lima, Lisa M Arellano, Martha Holloway, Stacie Shepard, Marian McMillan, Stephanie Khoury, Hanna Jean J Blood Med Review Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included. Dove Medical Press 2010-09-10 /pmc/articles/PMC3262317/ /pubmed/22282699 http://dx.doi.org/10.2147/JBM.S7158 Text en © 2010 Lima et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Lima, Lisa M
Arellano, Martha
Holloway, Stacie
Shepard, Marian
McMillan, Stephanie
Khoury, Hanna Jean
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
title Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
title_full Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
title_fullStr Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
title_full_unstemmed Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
title_short Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
title_sort efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262317/
https://www.ncbi.nlm.nih.gov/pubmed/22282699
http://dx.doi.org/10.2147/JBM.S7158
work_keys_str_mv AT limalisam efficacyofdasatinibforthetreatmentofintractablechronicmyeloidleukemia
AT arellanomartha efficacyofdasatinibforthetreatmentofintractablechronicmyeloidleukemia
AT hollowaystacie efficacyofdasatinibforthetreatmentofintractablechronicmyeloidleukemia
AT shepardmarian efficacyofdasatinibforthetreatmentofintractablechronicmyeloidleukemia
AT mcmillanstephanie efficacyofdasatinibforthetreatmentofintractablechronicmyeloidleukemia
AT khouryhannajean efficacyofdasatinibforthetreatmentofintractablechronicmyeloidleukemia

Ejemplares similares